导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -1.74% | 2731/4773 |
| 近一周 | -2.16% | 1353/5462 |
| 近一月 | -4.17% | 2270/5421 |
| 近一季 | -7.53% | 2436/5209 |
| 近半年 | -2.79% | 2021/4920 |
| 近一年 | 0.61% | 2524/4366 |
| 近两年 | 42.66% | 1755/2954 |
| 近三年 | 25.56% | 1254/2253 |
| 成立以来 | 135.16% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.32% 3131/4961 |
11.93% 2267/5312 |
- - |
- - |
| 2025 | 19.15% 2244/4813 |
-0.94% 2482/3635 |
1.96% 1984/4076 |
17.84% 2420/4524 |
0.10% 2217/4813 |
| 2024 | 15.23% 950/3463 |
2.73% 720/2808 |
-1.02% 895/3014 |
15.29% 1759/3129 |
-1.71% 1802/3463 |
| 2023 | -9.24% 1136/2656 |
3.91% 1091/2280 |
-3.87% 940/2385 |
-2.85% 768/2515 |
-6.47% 1793/2655 |
| 2022 | -19.18% 814/2207 |
-13.83% 850/1919 |
6.29% 731/2016 |
-13.24% 864/2113 |
1.70% 1174/2208 |
| 2021 | -3.53% 909/1822 |
-3.03% 744/1255 |
4.30% 901/1330 |
-5.55% 821/1466 |
0.99% 1028/1822 |
| 2020 | 27.82% 570/1250 |
-10.05% 741/1028 |
13.23% 636/1067 |
10.83% 507/1164 |
13.23% 378/1184 |
| 2019 | 35.97% 363/1092 |
26.38% 411/754 |
-0.16% 229/804 |
0.81% 460/850 |
6.90% 525/918 |
| 2018 | -22.57% 247/834 |
- - |
- - |
- - |
-11.87% 374/691 |
| 2017 | 20.67% 179/714 |
- - |
- - |
- - |
- - |
| 2016 | -8.01% 237/605 |
- - |
- - |
- - |
- - |
| 2015 | 9.58% 162/575 |
- - |
- - |
- - |
- - |
| 2014 | 46.65% 100/237 |
- - |
- - |
- - |
- - |
| 2013 | -4.55% 88/186 |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 华泰柏瑞沪深300ETF联接A VS. 长安沪深300非周期A(740101) |